Analysts Just Shipped A Dazzling Upgrade To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Estimates

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. Consensus estimates suggest investors could expect greatly increased statutory revenues and earnings per share, with the analysts modelling a real improvement in business performance. The stock price has risen 5.1% to US$26.25 over the past week, suggesting investors are becoming more optimistic. Could this big upgrade push the stock even higher?

Following the upgrade, the most recent consensus for Tarsus Pharmaceuticals from its four analysts is for revenues of US$64m in 2021 which, if met, would be a notable 15% increase on its sales over the past 12 months. Per-share losses are expected to creep up to US$0.36. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$44m and losses of US$0.94 per share in 2021. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.

Check out our latest analysis for Tarsus Pharmaceuticals

earnings-and-revenue-growth

The Bottom Line

The most important thing here is that analysts reduced their loss per share estimates for this year, reflecting increased optimism around Tarsus Pharmaceuticals' prospects. With a serious upgrade to expectations, it might be time to take another look at Tarsus Pharmaceuticals.

Still, the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Tarsus Pharmaceuticals analysts - going out to 2023, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.